Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox.

Abstract

Iron overload (IOL) due to transfusion-dependent anemia is a serious adverse effect in patients with myelofibrosis (MF). Recent studies have shown that the oral iron chelator deferasirox may prevent multiple organ damage due to IOL in MF. However, it is not clear whether deferasirox may contribute to revert transfusion-dependent anemia. Here, we present a patient with transfusion-dependent intermediate-2 MF according to the International Prognostic Scoring System treated with ruxolitinib in combination with deferasirox. In addition to a reduced serum ferritin level, the patient required less blood transfusions, ultimately resulting in long-lasting transfusion-free survival.

• Authors: Eugenio Piro, Maria Lentini, Luciano Levato, Antonio Russo, Stefano Molica
• Journal: Chemotherapy (Chemotherapy) Vol. 63 Issue 2 Pg. 107-110 (Apr 25 2018) ISSN: 1421-9794 [Electronic] Switzerland
• PMID: 29694973 (Publication Type: Journal Article)
• Copyright: © 2018 S. Karger AG, Basel.